COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
- DOI
- Language of the publication
- English
- Date
- 2023-04-21
- Type
- Article
- Author(s)
- Walmsley, Sharon L.
- Szadkowski, Leah
- Wouters, Bradly
- Clarke, Rosemarie
- Colwill, Karen
- Rochon, Paula
- Brudno, Michael
- Ravindran, Rizanni
- Raboud, Janet
- McGeer, Allison
- Oza, Amit
- Graham, Christopher
- Silva, Amanda
- Manase, Dorin
- Maksymowsky, Peter
- Parente, Laura
- Dayam, Roaya Monica
- Simpson, Jacqueline
- Pasculescu, Adrian
- Gingras, Anne-Claude
- Publisher
- Cell Press
Abstract
We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30–50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild.
Subject
- Health
Keywords
- Health sciences,
- Public health,
- Immunology,
- Immune response,
- Microbiology
Rights
Peer review
Yes
Open access level
Gold
Identifiers
- ISSN
- 2589-0042
Article
- Journal title
- iScience
- Journal volume
- 26
- Journal issue
- 4
- Article number
- 106506
- Accepted date
- 2023-03-22
- Submitted date
- 2022-12-23
Citation(s)
Walmsley SL, Szadkowski L, Wouters B, et al. COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. iScience. 2023;26(4):106506. doi:https://doi.org/10.1016/j.isci.2023.106506